Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02331368 · MORE INFO

Limitations, agreements, and source contact

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma · Source last updated 2018-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study was terminated during a pending major amendment after interim analysis and until the FDA mandate of the discontinuation of any combination therapy of MK-3475 and lenalidomide.
point Of Contact
email
pawarode@umich.edu
organization
University of Michigan Comprehensive Cancer Center
phone
734-936-8785
title
Dr. Attaphol Pawarode, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study was terminated during a pending major amendment after interim analysis and until the FDA mandate of the discontinuation of any combination therapy of MK-3475 and lenalidomide.
point Of Contact
email
pawarode@umich.edu
organization
University of Michigan Comprehensive Cancer Center
phone
734-936-8785
title
Dr. Attaphol Pawarode, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice